Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteome analyses of two ovarian clear cell carcinoma cell lines with or without ARID1A manipulation

ABSTRACT: ARID1A, which encodes a component of the SWI/SNF chromatin-remodeling complex, is commonly mutated in ovarian clear cell carcinoma and many other cancer types. We used label-free LC-MS/MS to identify ARID1A-dependent proteome changes in ovarian clear cell carcinoma cell lines. In our first analysis, we compared ARID1A-wildtype ovarian clear cell carcinoma cell line OVCA429 with or without ARID1A CRISPR knockout. In a complementary analysis, we compared ARID1A-mutated ovarian clear cell carcinoma cell line OVISE with or without ARID1A overexpression using a tet-inducible promoter.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: David W. Speicher

PROVIDER: MSV000079904 | MassIVE | Wed Jul 13 05:35:00 BST 2016

SECONDARY ACCESSION(S): PXD004570

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The proteome of clear cell ovarian carcinoma

Project description:Clear cell ovarian carcinoma (CCOC) is the second most common subtype of epithelial ovarian carcinoma. Late stage CCOC is not responsive to gold-standard chemotherapy and result in suboptimal outcome for patients. In-depth molecular insight is urgently needed to stratify the disease and drive therapeutic development. We conducted global proteomics in 192 cases of CCOC comparing to other epithelial ovarian carcinoma subtypes.

2022-09-02 | PXD032355 | Pride

MiR-146a-5p and miR-191-5p as novel diagnostic marker candidates for ovarian clear cell carcinoma

Project description:Ovarian cancer is a malignant gynecologic disease rarely diagnosed in the early stages. Among ovarian cancers, clear cell carcinoma has a poor prognosis due to its malignant potential. MicroRNAs (miRNAs) regulate gene expression in cells by suppressing the translation of the target gene or by degrading the target mRNA. They are also secreted from the cells in the blood, binding to the proteins or lipids and assisting in cell-cell communication. Hence, serum miRNAs can also be diagnostic biomarkers for ovarian cancer. This study investigated and identified specific miRNAs for ovarian clear cell carcinoma and compared them to those of ovarian endometrioma in healthy patients. CA125, an ovarian tumor marker, did not differ between patients with ovarian clear cell carcinoma, endometriosis, or healthy controls. Four miRNAs (miR-146a-5p, miR-191-5p, miR-484, and miR-574-3p) were analyzed. The miR-146a-5p and miR-191-5p expression levels were significantly increased in the serum samples from the patients with ovarian clear cell carcinoma compared to the healthy controls but not in the patients with endometriosis (P < 0.05). Furthermore, the bioinformatics analysis showed that CCND2 and NOTCH2 were the candidate target genes of miR 146a-5p and miR-191-5p. In conclusion, our results showed that miR 146a-5p and miR-191-5p might be useful as early and non-invasive diagnostic tools in ovarian clear cell carcinoma. These miRNAs can help in distinguishing between ovarian clear cell carcinoma and ovarian endometrioma. To the best of our knowledge, no studies have screened any candidates specifically for clear cell carcinoma.

2023-10-06 | GSE239685 | GEO

Transcriptome analysis of ovarian and uterine clear cell malignancies

Project description:We performed RNA Sequencing on eleven ovarian clear cell carcinoma and five uterine clear cell carcinoma patients to identify the unique transcriptional expression profiles of clear cell uterine and ovarian cancer, and investigates correlations with demographic factors and tumor characteristics, such as stage and PD-L1 immunohistochemical expression.

2020-12-22 | GSE160692 | GEO

Immune subtype of ovarian clear cell carcinoma

Project description:Immune subtype of ovarian clear cell carcinoma

| PRJNA529652 | ENA

RNA-Seq expression profiling of clonal populations from the OCI-C5x patient-derived ovarian clear cell carcinoma cell line

Project description:Intratumoral heterogeneity is well-recognized but its impact on tumor progression is unclear. Here, we derived unbiased clonal populations from OCI-C5x, a patient-derived ovarian clear cell carcinoma cell line, and assessed their tumorigenicity and tracked their fate during tumor progression. Results provide insight into intratumoral heterogeneity of clear cell carcinoma transcriptomes.

2020-09-11 | GSE123426 | GEO

Characterization of Mutational Status, Spheroid Formation, and Drug Response of a New Genomically-Stable Human Ovarian Clear Cell Carcinoma Cell Line, 105C (Affymetrix)

Project description:Ovarian clear cell carcinoma (OCCC) is a rare subtype of gynecological cancer for which well-characterized and authenticated model systems are scarce. We provide an extensive characterization of ‘105C’, a cell line generated from an adenocarcinoma of the clear cell histotype using targeted next-generation sequencing, cytogenetic microarrays, along with analyses of AKT/mTOR signaling. We report that that the 105C cell line is a bona fide OCCC cell line, carrying PIK3CA, PTEN, and ARID1A gene mutations, consistent with OCCC, yet maintain a stable genome as reflected by low copy number variation. Unlike KOC-7c, TOV-21G, and RMG-V OCCC lines also mutated for the above genes, the 105C cells do not carry mutations in mismatch repair genes. Importantly, we show that 105C cells exhibit greater resistance to mTOR inhibition and carboplatin treatment compared to 9 other OCCC cell lines in 3D spheroid cultures. This resistance may be attributed to 105C cells remaining dormant in suspension culture which surprisingly, contrasts with several other OCCC lines which continue to proliferate in long-term suspension culture. 105C cells survive xenotransplantation but do not proliferate and metastasize. Collectively, we show that the 105C OCCC cell line exhibits unique properties useful for the pre-clinical investigation of OCCC pathobiology. Copy number variation was determined for multiple Ovarian Clear Cell Carcinomas

2020-11-01 | GSE160569 | GEO

Transcription profiling of 12 human ovarian clear cell carcinoma cell lines

Project description:12 ovarian clear cell carcinoma cell lines were transcriptomically profiles using the illumina human v6 chip

2008-11-13 | E-TABM-540 | biostudies-arrayexpress

The microRNA profiles of ovarian clear cell carcinoma

Project description:The microRNA profiles of ovarian clear cell carcinoma

| PRJNA826962 | ENA

DNA Methylation Profiles of Ovarian Clear Cell Carcinoma

Project description:DNA Methylation Profiles of Ovarian Clear Cell Carcinoma

| PRJNA767374 | ENA

Transcriptomic Analyses of Ovarian Clear-Cell Carcinoma with Concurrent Endometriosis

Project description:Endometriosis, a benign inflammatory disease whereby endometrial-like tissue grows outside the uterus, is a risk factor for endometriosis-associated ovarian cancers. In particular, ovarian endometriomas, cystic lesions of deeply invasive endometriosis, are considered the precursor lesion for ovarian clear-cell carcinoma (OCCC). To explore the transcriptomic landscape, OCCC from women with pathology-proven concurrent endometriosis (n = 4) were compared to benign endometriomas (n = 4) by bulk RNA and small-RNA sequencing.

2023-07-29 | GSE230956 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data